| 000 | 01469 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250517142326.0 | ||
| 264 | 0 | _c20180604 | |
| 008 | 201806s 0 0 eng d | ||
| 022 | _a2160-7648 | ||
| 024 | 7 |
_a10.1002/cpdd.314 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRoy-Chowdhury, Jayanta | |
| 245 | 0 | 0 |
_aDrug- and Drug Abuse-Associated Hyperbilirubinemia: Experience With Atazanavir. _h[electronic resource] |
| 260 |
_bClinical pharmacology in drug development _cMar 2017 |
||
| 300 |
_a140-146 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAtazanavir Sulfate _xadministration & dosage |
| 650 | 0 | 4 |
_aBilirubin _xblood |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlucuronosyltransferase _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aGlutathione Transferase _xmetabolism |
| 650 | 0 | 4 |
_aHIV Protease Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aHepatocytes _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyperbilirubinemia _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 |
_aRitonavir _xadministration & dosage |
| 650 | 0 | 4 |
_aSubstance-Related Disorders _xcomplications |
| 700 | 1 | _aRoy-Chowdhury, Namita | |
| 700 | 1 | _aListowsky, Irving | |
| 700 | 1 | _aWolkoff, Allan W | |
| 773 | 0 |
_tClinical pharmacology in drug development _gvol. 6 _gno. 2 _gp. 140-146 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cpdd.314 _zAvailable from publisher's website |
| 999 |
_c26939209 _d26939209 |
||